Physician profile
Frances E Loftus
NPI 1851381438
$77,378.58
in general payments reported to CMS, 2019-2025
31 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,819 · 2020: $13K · 2021: $10K · 2022: $4,114 · 2023: $5,945 · 2024: $11K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $4,533 · Travel and Lodging: $3,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,775.00 |
| Food and Beverage | $4,532.93 |
| Travel and Lodging | $3,624.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $59,009.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Allergan, INC. | $7,688.16 | 2019-2020 | |
| Abbvie INC. | $3,976.56 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,707.39 | 2019-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $886.26 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Mylan Specialty L.P. | $739.02 | 2019-2024 | Yupelri, Yupelri |
| Regeneron Healthcare Solutions, INC. | $405.76 | 2019-2025 | Dupixent |
| Philips North America LLC | $277.77 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Genzyme Corporation | $276.00 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $241.80 | 2019-2025 | Uptravi, Opsumit |
| Grifols USA, LLC | $127.24 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $121.36 | 2019-2023 | Xolair |
| Insmed, INC. | $115.17 | 2019-2025 | Arikayce |
| Amgen INC. | $111.58 | 2022-2024 | Tezspire |
| Harmony Biosciences LLC | $100.67 | 2021-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $98.00 | 2023-2024 | Lumryz |
| Novartis Pharmaceuticals Corporation | $71.39 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $62.13 | 2020-2025 | |
| Verona Pharma, INC. | $54.04 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $50.10 | 2019-2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $47.26 | 2021-2024 | |
| Electromed, INC. | $44.40 | 2019-2024 | Smartvest |
| Merck Sharp & Dohme LLC | $39.97 | 2019-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.72 | 2023 | Lifevest |
| Sunovion Pharmaceuticals INC. | $17.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.34 | 2020 | |
| Sun Pharmaceutical Industries INC. | $14.27 | 2025 | |
| Lilly USA, LLC | $13.93 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $13.89 | 2021 | |
| Portola Pharmaceuticals, LLC | $13.43 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Loftus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.